Last updated: February 13, 2026
Market Analysis and Price Projections for DALIRESP (Roflumilast)
Market Overview
DALIRESP (roflumilast) is an oral phosphodiesterase-4 (PDE4) inhibitor approved primarily for the treatment of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations. It functions as an anti-inflammatory agent reducing frequency and severity of COPD exacerbations, which positions it within the niche of maintenance therapies for moderate to severe COPD.
The drug's market entry occurred in 2011, with regulatory approvals across North America, Europe, and Japan. The global COPD drug market was valued at approximately $13 billion in 2022, with DALIRESP accounting for a small but stable segment due to its specific indication and pricing.
Market Dynamics
Key factors influencing Market:
- Treatment landscape: COPD management increasingly favors inhaled corticosteroids, bronchodilators, and combination therapies. Oral agents like DALIRESP are used as adjuncts for patients with frequent exacerbations despite inhaled therapy.
- Pricing and reimbursement policies: Reimbursement varies globally, influencing adoption rates.
- Competition: PDE4 inhibitors like Azithromycin and other emerging therapies pose competition.
- Prescription patterns: Physicians' familiarity and perceived efficacy influence utilization.
Market penetration: DALIRESP has maintained a niche position, primarily prescribed for patients unresponsive or intolerant to inhaled therapies. Its market share remains limited because of its oral route, side-effect profile, and competition from inhaled combinations.
Current Pricing and Reimbursement Status
- United States: Average wholesale price (AWP): ~$20 per tablet (0.5 mg, 30-tablet pack). Estimated annual treatment cost: ~$7,300.
- Europe: Prices are similar, with variations based on country-specific pricing policies, typically ranging from €150-€200 per month.
- Japan: Similar pricing, but with stricter reimbursement criteria.
Reimbursement policies generally restrict DALIRESP to severe COPD patients after failure of or intolerance to inhaled therapies, impacting sales volume.
Price Projections (2023-2030)
Projection assumptions:
- Market growth: Modest annual growth rate of approximately 2% in the COPD market.
- Market share: DALIRESP is expected to sustain its current niche, with potential expansion into broader COPD populations due to new clinical data.
- Pricing: Slight increases of 2-3% annually, aligned with inflation and healthcare costs.
| Year |
Estimated Annual Revenue |
Average Price per Pack |
Comments |
| 2023 |
$320 million |
$7,500 |
Stable, modest growth |
| 2025 |
$340 million |
$7,700 |
Slight expansion in use |
| 2027 |
$350 million |
$8,000 |
Increased adoption, pipeline support |
| 2030 |
$370 million |
$8,200 |
Market stabilization |
Note: These projections assume no major patent expirations or new competitors entering at scale. Any patent cliff or regulatory change could impact prices significantly.
Patent and Regulatory Considerations
- The primary patent for DALIRESP expired in 2020 in the U.S., but formulations and method-of-use patents have extended exclusivity until 2025-2027 in various jurisdictions.
- Generic versions could enter the market post-patent expiry, potentially reducing prices by 30-50%, depending on regulatory and market dynamics.
Key Takeaways
- DALIRESP remains a niche but stable therapy within COPD treatment.
- Pricing is influenced by regional reimbursement and competition, with slight annual increases projected.
- Market size growth is slow, constrained by existing treatment algorithms and competition.
- Patent protections extending until 2025-2027 provide exclusivity, after which price erosion is likely.
- Potential for market expansion hinges on clinical data supporting broader use or new formulations.
FAQs
Q1: What is DALIRESP's main indication?
A1: Treatment of severe COPD associated with chronic bronchitis and history of exacerbations.
Q2: How does DALIRESP's price compare internationally?
A2: Prices are similar across major markets, generally €150-€200 per month, with slight regional variations.
Q3: What factors could lead to a decline in DALIRESP's market share?
A3: Entry of generic versions post-patent expiry, new inhaled therapies, or clinical trial failures impacting its perceived efficacy.
Q4: Are there emerging formulations of DALIRESP?
A4: No current announced formulations, but research into combination therapies or extended-release formulations is ongoing.
Q5: How will patent expiry affect DALIRESP?
A5: It could lead to generic competition, reducing prices and sales volume, with an estimated impact of 30-50% price decline.
References
[1] IQVIA, Global COPD Market Analysis, 2022.
[2] FDA, Drug Approval Package for DALIRESP, 2011.
[3] European Medicines Agency, Summary of Product Characteristics for DALIRESP, 2011-2022.
[4] Market data from EvaluatePharma and IQVIA, 2023.
